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O. Fasan / Biol Blood Marrow Transplant 20 (2014) 1e32stimulation of speciﬁc immune responses to CMV in pa-
tients with AML after SCT is potent enough. However, this
effect cannot be expected from new antiviral drugs towards
CMV discussed elsewhere.
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outcomes of mobilizing with high dose etoposide plus GCSF
as compared to cyclophosphamide plus GCSF and platinum
based salvage regimens plus GCSF. Etoposide plus GCSF isPeripheral blood progenitor cell (PBPC) mobilization is
the ﬁrst step in the autologous stem cell transplant (ASCT)
procedure. The regimen used for PBPC mobilization affects
not just the cost of ASCT but also the patient’s total transplant
experience. We often focus on the absolute numeric pro-
genitor cell yield as measured by the CD34þ cell dose in the
mobilized graft; however, the optimal mobilization strategy
should be judged on more than this metric alone. The PBSC
graft quantity and quality affects engraftment kinetics and,
although controversial, may inﬂuence relapse-free survival,
overall survival, and the development of post-transplant
complications such as therapy-related myelodysplastic syn-
drome and acute myeloid leukemia (tMDS/AML) [1-3]. The
choice of whether to mobilize patients using either gran-
ulocyte colony-stimulating factor (G-CSF) alone, G-CSF plus
plerixafor, or chemotherapy plus G-CSF is usually based on
the patient’s disease status, prior therapy, predicted poor
mobilizer status, transplant center protocol, cost consider-
ations, and the individual patient situation. Chemotherapy
plus G-CSF is generally viewed as an attractive strategy to
achieve needed anti-tumor effect and to ensure at least an
adequate (2  106/kg CD34þ cells) or a successful (5  106/
kg CD34þ cells) apheresis yield at a reasonable cost.not a new mobilization regimen, however its utilization
declined following concerns regarding the reported higher
incidence of tMDS/AML following etoposide based mobili-
zation and ASCT [3]. This is probably not so and there are
reports indicating that the incidence of t(MDS/AML) after
etoposide is not signiﬁcantly increased [5e7]. The dose of
etoposide utilized in this retrospective study by Shin Young
Hyun et al. was 1.5g/m2. This dose is lower than the more
conventional 2g/m2. It however appears to have led to an
overall greater number of successful ( 5  106/kg CD34þ
cells) mobilizations at 86% compared to cyclophosphamide
4g/m2 plus GCSF and the platinum based regimens (ICE,
DHAP and ESHAP) plus GCSF at 45% and 61% respectively
(p¼0.004). The success of this lower dose is in keeping with
the observation by Kanfer et al., that reducing the dose of
etoposide to 1.6g/m2 or 1.8g/m2 resulted in adequate and
successful mobilizations compared to higher doses. An even
lower dose of etoposide (0.75g/m2) was utilized with suc-
cess in patients with multiple myeloma, some of whom
were predicted poor mobilizers [8]. Consistent across all
reports of high and intermediate dose etoposide based
mobilization is the high incidence of neutropenic fever
compared to growth factor based strategies where the
incidence is zero. The incidence of 67% in this report is
higher than previously reported rates that range from of
17e 27%. This complication unfortunately increases the cost
and inconvenience to patients due to the need for read-
mission for intravenous antibiotics. There is more myelo-
suppression and utilization of blood products with all
chemo-mobilization based strategies; however in this
report etoposide plus GCSF induced a signiﬁcantly lower
O. Fasan / Biol Blood Marrow Transplant 20 (2014) 1e3 3platelet nadir compared with the other chemotherapy
regimens (p¼0.010).
In comparing different mobilization regimens, it is clear
that wemust evaluate not just the total CD34þ yield from all
the apheresis procedures but also the ability to achieve an
accepted disease-speciﬁc CD34þ cell yield on day 1 of
collection. This metric is particularly useful because it mea-
sures not just the effectiveness of a particular mobilization
agent but is also a surrogate for a portion of the cost asso-
ciated with collection and of patient inconvenience. The
percentage of patients reaching a successful collection
(5  106/kg CD34þ cells) on day 1 satisﬁes the dose
requirement for patients with lymphoma for whom 1 ASCT
procedure is planned. Using this metric, Shin Young Hyun
et al, have shown that etoposide plus G-CSF is probably a
superior regimen because it achieved this metric in 72%
compared with 13% for cyclophosphamide plus G-CSF and
26% for platinum-based regimens (P < .001). We must
reserve judgment on this conclusion, however, because this
was a retrospective study.
No comment on progenitor cell mobilization would be
complete without some indication as to the place and role of
plerixafor. This CXCR4 antagonist has transformed the
landscape of PBSCmobilization due to its capacity to increase
mobilization yields signiﬁcantly even in predicted poor
mobilizers, effectively reducing the number of days required
for mobilization and reducing patient inconvenience. The
perceived high cost has prevented widespread adoption. The
cost-to-beneﬁt ratio of plerixafor is made more favorable by
using a “just in time” or “on demand” strategy whereby its
use depends on day 4 peripheral blood CD34þ. We must also
remember that plerixafor signiﬁcantly increases the number
of patients achieving the target CD34þ cells on day 1 and is
able to rescue failing mobilizations, thereby preventing
costly second mobilizations. Costa et al. [9] published an
algorithm of peripheral blood CD34þ thresholds at which
the utilization of plerixafor would make medical and eco-
nomic sense. Going forward, evaluation of mobilization
regimens should include comparisons with G-CSF plus (on
demand) plerixafor. Before declaring 1 particular mobiliza-
tion strategy the winner, we must evaluate other equally
important outcomes, including the total cost of mobilization,
incidence of neutropenic fever, blood product utilization,
engraftment kinetics, relapse-free survival, overall survival,
and the development of tMDS/AML.
We also need to study the impact other cellular compo-
nents of a graft have on outcomes. We know that grafts
contain not just CD34þ progenitor cells but also dendritic
cells, natural killer cells, T regulatory cells, CD3 þ T cells,
CD19þ B cells, and unfortunately mobilized tumor cells.
Dean et al. [1] prospectively studied the impact of dendritic
cell populations (DC1 and DC2) on survival after ASCT in
patients with diffuse large B cell lymphoma and concluded
that higher graft dendritic cell content and post-transplant
recovery improves survival in this population. Prospective
study of the effect these other cell populations have on
engraftment and survival outcomes is required because the
differing mobilization strategies probably affect them
differently. This may provide an opportunity for in vivo graft
engineering, whereby a particular mobilization regimen isselected based on its ability to maximize or minimize
particular cell subsets in an attempt to improve patient
outcomes.
So what is the optimal mobilization strategy? It is one
that results in the collection of the required number of pro-
genitor cells in the most cost-effective manner, in the least
amount of days, and causes little disruption to the patient’s
quality of life. It would ideally have a low or no incidence of
neutropenic fever and not increase the need for blood
product transfusions. There should be no increase in the
incidence of tMDS/AML, and it wouldmaximize the potential
not just for rapid hematopoietic recovery but also for overall
survival.
PBPC mobilization is complex, and a one-size-ﬁts-all
approach is a simplistic strategy. Success will depend on
each transplant center developing its own mobilization al-
gorithms, taking into consideration patient-, disease-, and
center-speciﬁc variables to achieve the desired outcomes
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